News

Astellas’ Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for $609 Million

Tokyo, Japan – June 30, 2011 — Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that Prosidion_s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a

Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million

New York, NY (US) – April 4, 2011 — Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million. Lexiscan® (regadenoson) is a market-leading pharmacologic stress agent